For research use only. Not for therapeutic Use.
TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent[1][2][4].
TT-232 (10 μg/mL, 48 h) induces apoptosis in human colon (HT-29 and SW620), pancreatic (818), leukemia (K-562), melanoma (WM 938/B, M-1 and EP) and lymphoma (HT-58) tumor cell lines[1].
TT-232 (20-30 μg/mL, 24 h) shows antiproliferative effect on various human tumor cell lines[2].
TT-232 (15-750 μg/kg/day, twice a day) inhibits tumor growth in mice transplanted with Colon 26 cell[2].
TT-232 (0.6 or 15 μg/kg s.c or i.p.) shows antitumor effect on P-388 rodent lymphocytic leukemia tumor mice[3].
TT-232 (7.5-20 μg/kg, i.v.) inhibits Carrageenin-induced paw oedema in rats[4].
| Catalog Number | M095061 |
| CAS Number | 147159-51-1 |
| Synonyms | (4R,7S,10R,13S,16R)-7-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-16-[[(2R)-2-amino-3-phenylpropanoyl]amino]-13-[(4-hydroxyphenyl)methyl]-10-(1H-indol-3-ylmethyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide |
| Molecular Formula | C45H58N10O9S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C45H58N10O9S2/c1-25(56)38(39(48)58)55-45(64)37-24-66-65-23-36(53-40(59)31(47)19-26-9-3-2-4-10-26)44(63)51-34(20-27-14-16-29(57)17-15-27)42(61)52-35(21-28-22-49-32-12-6-5-11-30(28)32)43(62)50-33(41(60)54-37)13-7-8-18-46/h2-6,9-12,14-17,22,25,31,33-38,49,56-57H,7-8,13,18-21,23-24,46-47H2,1H3,(H2,48,58)(H,50,62)(H,51,63)(H,52,61)(H,53,59)(H,54,60)(H,55,64)/t25-,31-,33+,34+,35-,36+,37+,38+/m1/s1 |
| InChIKey | SNAJPQVDGYDQSW-DYCFWDQMSA-N |
| SMILES | CC(C(C(=O)N)NC(=O)C1CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)O |
| Reference | [1]. Szende B, et al. TT-232: a somatostatin structural derivative as a potent antitumor drug candidate. Anticancer Drugs. 2003 Sep;14(8):585-8. [2]. Kéri G, et al. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12513-8. [3]. Tejeda M, et al. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models. Anticancer Res. 2005 Jan-Feb;25(1A):325-30. [4]. Pintér E, et al. Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366(2):142-50. |
